Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma ( DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

被引：9
|
作者：
Casulo, Carla [1 ]
Santoro, Armando [2 ,3 ]
Ando, Kiyoshi [4 ]
Le Gouill, Steven [5 ]
Ruan, Jia [6 ]
Radford, John [7 ,8 ]
Arcaini, Luca [9 ,10 ]
Pinto, Antonello [11 ]
Bouabdallah, Reda [12 ]
Izutsu, Koji [13 ]
Rule, Simon [14 ]
Munoz, Javier [15 ]
Casadebaig, Marie-Laure [16 ]
Fox, Brian [17 ]
Rettby, Nils [16 ]
Dell'Aringa, Justine [17 ]
Delarue, Richard [16 ]
Newhall, Kathryn [17 ]
Czuczman, Myron [17 ]
Cartron, Guillaume [18 ]
机构：
[1] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA
[2] Humanitas Univ, Rozzano Milan, Italy
[3] Humanitas Clin & Res Ctr, Rozzano Milan, Italy
[4] Tokai Univ, Sch Med, Isehara, Kanagawa, Japan
[5] CHU Nantes, Nantes, France
[6] Weill Cornell Med, New York, NY USA
[7] Univ Manchester, Manchester, Lancs, England
[8] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[9] Fdn IRCCS Policlin San Matteo, Pavia, Italy
[10] Univ Pavia, Pavia, Italy
[11] Fdn G Pascale, Ist Nazl Tumori IRCCS, Naples, Italy
[12] Inst Paoli Calmettes, Marseille, France
[13] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
[14] Univ Plymouth, Plymouth, Devon, England
[15] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[16] Celgene Int, Boudry, Switzerland
[17] Celgene Corp, Seattle, WA USA
[18] Ctr Hosp Univ Montpellier, Montpellier, France
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124102
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5320
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
    Kim, Won-Seog
    Kim, Tae Min
    Cho, Seok-Goo
    Jarque, Isidro
    Iskierka-Jazdzewska, Elzbieta
    Poon, Michelle Limei
    Prince, H. Miles
    Oh, Sung Yong
    Lim, Francesca
    Carpio, Cecilia
    Tran-Der Tan
    Ayyappan, Sabarish
    Gutierrez, Antonio
    Li, Jingjin
    Ufkin, Melanie
    Zhu, Min
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Walewski, Jan
    BLOOD, 2022, 140 : 1070 - 1071
  • [32] Polatuzumab vedotin (Pola) plus rituximab (R) plus lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.
    Diefenbach, Catherine S. Magid
    Abrisqueta, Pau
    Gonzalez-Barca, Eva
    Panizo, Carlos
    Perez, Jose Maria Arguinano
    Miall, Fiona
    Bastos-Oreiro, Mariana
    Lopez-Guillermo, Armando
    Banerjee, Lalita
    McMillan, Andrew
    Hirata, Jamie
    Musick, Lisa
    Saha, Sourish
    Croft, Brandon
    Seymour, Erlene Kuizon
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO
    Martin Garcia-Sancho, A.
    Baile, M.
    Rodriguez, G.
    Dlouhy, I.
    Sancho, J. M.
    Jarque, I.
    Gonzalez-Barca, E.
    Salar, A.
    Espeso, M.
    Grande, C.
    Bergua, J.
    Montes-Moreno, S.
    Redondo, A.
    Enjuanes, A.
    Campo, E.
    Lopez-Guillermo, A.
    Caballero, D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (02) : 202 - 211
  • [34] Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study
    Jurczak, Wojciech
    Zinzani, Pier Luigi
    Gaidano, Gianluca
    Goy, Andre
    Provencio, Mariano
    Nagy, Zsolt
    Robak, Tadeusz
    Maddocks, Kami J.
    Buske, Christian
    Ambarkhane, Sumeet
    Winderlich, Mark
    Dirnberger-Hertweck, Maren
    Endell, Jan
    Blum, Kristie A.
    BLOOD, 2016, 128 (22)
  • [35] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group
    Martin, Alejandro
    Redondo, Alba M.
    Dlouhy, Ivan
    Salar, Antonio
    Gonzalez-Barca, Eva
    Canales, Miguel
    Montes-Moreno, Santiago
    Ocio, Enrique M.
    Lopez-Guillermo, Armando
    Caballero, Dolores
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 245 - 252
  • [36] Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.
    Dickinson, Michael
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Tomasz
    Offner, Fritz
    Trneny, Marek
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Balari, Anna Sureda
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years
    Duell, Johannes
    Jurczak, Wojciech
    Liberati, Anna Marina
    Halka, Janusz
    Carbo, Esther Pena
    Costa, Pau Abrisqueta
    Maddocks, Kami J.
    Dreyling, Martin
    Rosenwald, Andreas
    Bakuli, Abhishek
    Amin, Aasim
    Gurbanov, Konstantin
    Salles, Gilles
    BLOOD, 2022, 140 : 6596 - 6598
  • [38] Epcoritamab plus GemOx Induces Deep, Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2
    Cordoba, Raul
    Jorgensen, Judit
    Belada, David
    Costello, Regis
    Trneny, Marek
    Vitolo, Umberto
    John Lewis, David
    Karimi, Yasmin H.
    Sureda, Anna
    Andre, Marc
    Wahlin, Bjorn E.
    Lugtenburg, Pieternella J.
    Jiang, Tony
    Abbas, Aqeel
    Song, Yaou
    Risum, Malene
    Brody, Joshua D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S468 - S469
  • [39] LENALIDOMIDE MONOTHERAPY IS CLINICALLY ACTIVE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A POOLED ANALYSIS OF DATA FROM 2 PHASE II STUDIES (NHL-002/003)
    Czuczman, M.
    Vose, J.
    Zinzani, P. L.
    Reeder, C.
    Buckstein, R.
    Haioun, C.
    Bouabdallah, R.
    Polikoff, J.
    Ervin-Haynes, A.
    Witzig, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 239 - 239
  • [40] Subcutaneous Epcoritamab With Rituximab plus Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial
    Falchi, Lorenzo
    Leppa, Sirpa
    Wahlin, Bjorn E.
    Nijland, Marcel
    Christensen, Jacob Haaber
    De Vos, Sven
    Holte, Harald
    Linton, Kim M.
    Abbas, Aqeel
    Wang, Liwei
    Dinh, Minh
    Elliott, Brian
    Belada, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S392 - S392
12345